Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects
- 17 April 2003
- journal article
- research article
- Published by Wiley in Clinical Endocrinology
- Vol. 58 (5), 562-571
- https://doi.org/10.1046/j.1365-2265.2003.01753.x
Abstract
Objective Sex differences are found in most components of the insulin resistance syndrome and the associated cardiovascular risk profile. These differences are attributed to sex‐specific sex steroid profiles, but the effects of sex steroids on the individual components of the insulin resistance syndrome remain incompletely understood. design Prospective, intervention study. subjects In 37 young (age range 16–36 years), nonobese [body mass index (BMI) < 29], transsexual subjects, effects of ethinyl oestradiol (100 µg/day) + cyproterone acetate (100 mg/day) administration were evaluated in 20 male‐to‐female transsexuals and of testosterone‐ester administration [250 mg intramuscularly (i.m.)/2 weeks] in 17 female‐to‐male transsexuals. measurements We studied lipid spectrum, postheparin hepatic lipase (HL) and lipoprotein lipase (LPL) activity, blood pressure, glucose utilization (by euglycaemic hyperinsulinaemic clamp), and fat areas (by magnetic resonance imaging) at baseline and during 1‐year cross‐sex hormone administration. results Oestrogens + antiandrogens increased high‐density lipoprotein (HDL)‐cholesterol and decreased LDL‐cholesterol, and HL activity, which are considered beneficial. But this combination also increased triglycerides, blood pressure, subcutaneous fat and visceral fat, and decreased the LDL‐particle size, LPL activity and insulin sensitivity, which are all considered detrimental. Testosterone reduced HDL‐cholesterol and the LDL‐particle size, and increased triglycerides and HL activity. An android fat distribution was induced (i.e. decreased subcutaneous and increased visceral fat). Blood pressure, total and LDL‐cholesterol, LPL activity and insulin sensitivity were mainly unaffected. conclusions The effects of cross‐sex hormone treatment – in the dosages used in this study – in healthy, nonobese, young transsexual subjects do not show unequivocally that female sex steroids, given in large amounts to male subjects, have beneficial effects on cardiovascular profile and that high dose testosterone administration to female subjects is detrimental with respect to cardiovascular risk.Keywords
This publication has 55 references indexed in Scilit:
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Androgen Replacement Therapy in the Aging Male--A Critical EvaluationJournal of Clinical Endocrinology & Metabolism, 2001
- Effects of Estrogen Replacement on the Progression of Coronary-Artery AtherosclerosisNew England Journal of Medicine, 2000
- Effects of Methyltestosterone on Insulin Secretion and Sensitivity In WomenJournal of Clinical Endocrinology & Metabolism, 1998
- Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal WomenJAMA, 1998
- Suppression of Endogenous Testosterone in Young Men Increases Serum Levels of High Density Lipoprotein Subclass Lipoprotein A-I and Lipoprotein(a)Journal of Clinical Endocrinology & Metabolism, 1997
- The relationship of natural androgens to coronary heart disease in males: a reviewAtherosclerosis, 1996
- Effect of hepatic lipase on LDL in normal men and those with coronary artery disease.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1993
- Blood pressure, stroke, and coronary heart disease *1Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution biasThe Lancet, 1990
- Sex, plasma lipoproteins, and atherosclerosis: Prevailing assumptions and outstanding questionsAmerican Heart Journal, 1987